Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Quincy S. Chu
Abstract
The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driver mutations in non-small cell lung cancer. These driver mutations can be categorized into mutations in or near the kinase domain, gene amplification or fusion. In this review, BRAF V600E, EGFR and HER-2 exon 20 mutation, FGFR1–4, K-RAS, MET, neuregulin-1, NRTK, PI3K/AKT/mTOR, RET and ROS1 gene aberration and their therapeutics will be discussed.
Topics & Concepts
Anaplastic lymphoma kinaseCancer researchROS1Epidermal growth factor receptorMedicineMutationLung cancerAnaplastic large-cell lymphomaPI3K/AKT/mTOR pathwayERBB3Fusion geneProtein kinase domainCancerLymphomaBiologyGeneOncologySignal transductionAdenocarcinomaGeneticsImmunologyInternal medicineMalignant pleural effusionMutantLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies